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Abstract
Background: Mesh surgery for stress urinary incontinence or pelvic organ prolapse can result in 
complications such as mesh exposure, mesh extrusion, voiding dysfunction, dyspareunia and pain. There 
is limited knowledge or guidance on the effective management for mesh related complications.   
Objective: To determine the best management of mesh complications; a systematic review was 
conducted as part of the national clinical guideline ‘Urinary incontinence (update) and pelvic organ 
prolapse in women: management’. 
Search strategy: Search strategies were developed for each indicator of referral. 
Selection Criteria: Relevant Interventions included complete or partial mesh removal, mesh division and 
non-surgical treatments such as vaginal oestrogen.  
Data collection and analysis: Characteristics and outcome data were extracted, due to the heterogeneous 
nature, a narrative synthesis was conducted.  
Main Results: Twenty four studies were included, five provided comparative data and four studies stated 
the indication for referral.  Reported outcomes (including pain, dyspareunia, satisfaction, quality of life, 
incontinence, mesh exposure, and recurrence) and the reported incidence of these varied widely. 
Conclusions: The current evidence base is limited in quantity and quality, and does not permit firm 
recommendations to be made on the most effective management for mesh-related complications.  
Robust data is needed so effective management of mesh complications can be provided. 
Funding: The guideline referred to in this article was produced for the National Institute for Health and 
Care Excellence (NICE) as part of the national clinical guideline ‘Urinary incontinence (update) and pelvic 
organ prolapse in women: management’.
Key words: Stress urinary incontinence, pelvic organ prolapse, mesh revision 
Tweetable abstract: Systematic review demonstrates outcomes following mesh revision surgery are 
highly variable.
Introduction
Mesh-augmented surgery for stress urinary incontinence (SUI) and pelvic organ prolapse (POP) using 
minimally invasive surgical techniques and polypropylene mesh were widely adopted in the 1990’s.1 
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surgery 2-4; but the majority did not report long-term complications.  Reports of mesh-related 
complications are increasing 5, which has led to  warnings from the Scientific Commitee on Emerging and 
Newly Identified Health Risks (SCENIHR) and the Food and Drug Administration (FDA).6-8
Mesh surgery can result in mesh complications such as exposure, extrusion and infection, in addition to 
the complications following any procedure for incontinence and prolapse, such as voiding dysfunction, 
dyspareunia and pain.9, 10  Estimates of complications due to mesh surgery vary from 0 to 33%.11  A review 
of NHS patient data found 10% of women in England who had a midurethral mesh sling (MUS) implanted 
were admitted for a complication (which was not necessarily mesh related) within five years, with a  mesh 
removal rate of 3.3% over a 9 year period.12  
Despite concern about these potential complications, there is little evidence on how they should be 
managed.13, 14  Different indications may determine different treatment choices: e.g. a midline division of 
an MUS may be effective in resolving voiding dysfunction but may not  relieve pain.15 To date, there is no 
guidance on managing mesh-related complications.16
Study objective
We conducted a systematic review to determine the best treatment options for mesh complications 
according to the indication for referral: vaginal complications, pain, urinary complications and bowel 
complications. The review was conducted as part of the new national clinical guideline ‘Urinary 
incontinence (update) and pelvic organ prolapse in women: management’ released by the National 
Institute for Health and Care Excellence (NICE).17 
 
Methods
Following the NICE guidelines manual 18 we developed review protocols for each indication for referral 
which were approved by NICE in advance of the review being conducted.  These were published as part of 
the guideline. 17 
Patient and public involvement
The review was developed by a committee which includes lay members, who provided input at all stages 
of the review - protocol development, discussion of the evidence and drafting of recommendations.  
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Population
Only studies with women aged 18 years or older, who were experiencing complications - vaginal (e.g. 
exposure, extrusion and mesh infection), pain (e.g. sexual dysfunction/dyspareunia), urinary, or bowel 
symptoms - following mesh surgery for SUI, POP or both, were included. 
Types of studies
RCT, cohort studies and case series were considered for inclusion with the latter two required to have a 
minimum of 50 participants.  Case series were included only if no comparative data were available. 
Types of interventions
Relevant interventions included: partial or complete removal of mesh (vaginal, abdominal or 
laparoscopic), mesh trimming, vaginal oestrogen, antibiotics (systemic or local), pus drainage, vaginal 
dilation, vaginal reconstruction, vaginoplasty, pain management (including psychosexual counselling, local 
anaesthetic, physiotherapy, analgesia, and botulinum toxin), transurethral excision, and mesh division.
Outcomes
Relevant outcomes were: bowel complications, continued or repeated exposure/extrusion/infection, 
continued or repeat sexual dysfunction, health-related quality of life (HRQOL) , intraoperative 
complications (severe bleeding, requiring blood transfusion, and internal organ injury), long term 
complications (pain, mesh exposure or extrusion, de novo overactive bladder and sexual dysfunction), 
satisfaction, recurrence, and repeat surgery.  No relevant core outcome set currently exists for mesh 
revision surgery; therefore outcomes were selected according to known reported complications.  
Exclusion criteria
Studies only reporting rates of complications following mesh surgery were excluded, as were those that 
only described management of complications.  Studies not published in the English language were 
excluded.
Search strategy
Search strategies were developed for each indication (Appendix S1) and included medical subject 
headings and free text terms based on the eligibility criteria.  The search was conducted on Embase 
Classic + Embase (1947 onwards), Ovid MedLINE (R) In-process & Other Non-Indexed Citations and Ovid 









This article is protected by copyright. All rights reserved
each indication were: urinary complications 20th September 2017, vaginal complications 30th November 
2017, sexual dysfunction and pain complications 22nd November 2017, and bowel complications 26th 
March 2018.
Study selection
Retrieved titles and abstracts were imported into the National Guideline Alliance (NGA) in-house 
database.  Initial screening of titles and abstracts was conducted by one reviewer; a ten percent random 
sample was then screened by a second reviewer.  Full texts of potentially relevant articles were obtained 
and independently screened by two reviewers.  Any disagreements were resolved by discussion to reach a 
consensus between the two reviewers.  When they were unable to reach consensus, a third reviewer 
arbitrated.
Study synthesis
Characteristics and outcome data of the included studies were extracted by one reviewer, with a second 
reviewer checking all data for accuracy and completeness.  Due to the heterogeneous nature of the 
included studies, a narrative synthesis of the results was conducted.  
Validity assessment
The Cochrane ROBINS-I checklist was used to assess the risk of bias of observational studies,19 on seven 
domains: confounding bias, participant selection bias, intervention classification, bias due to deviations 
from intended interventions, missing data bias, outcome measurement bias, and reporting bias.   The tool 
was applied to each study by two review authors working independently, justification for judgements 
were recorded, and any discrepancies were resolved by discussion.  
Results
After removing duplicates, the search strategy returned 6,443 potentially eligible articles.  Abstract and 
title screening identified 184 full-text articles, of which twenty-four studies met the inclusion criteria and 
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Characteristics of included studies and a summary of outcomes comparing complete to partial mesh 
removal are presented in Table S1 and Table S2, respectively. One study reviewed a prospectively-
collected database 20, while  all other studies were retrospective; seventeen studies were conducted in 
the USA, three each in Germany 21-23 and France 24-26, and one in Taiwan 27. Five studies 15, 16, 25, 28, 29 
provided comparative data. 
Three studies concerned women specifically referred for pain, 15, 20, 30  two referred for vaginal 
complications15, 27 and one for those referred for urinary complications.31  No studies in women who were 
referred specifically because of bowel complications were identified.  Nineteen studies examined the 
general management of mesh complications, most reporting the range of indications women presented 
with. 
Only four studies specified that women underwent initial mesh surgery for POP14, 16, 23, 32 and eight 
specified that initial mesh surgery was for SUI15, 21, 26, 28, 29, 31, 33, 34.  The remaining studies included women 
who had initial mesh surgery for POP and/or SUI; but did not report outcomes separately for these 
women.  Also, they did not all report the same outcomes; therefore, the data could not be combined.  
None of the included studies provided data on the use of oestrogen or alternative therapies.
Quality of the evidence
All included studies were assessed using the ROBINS-I tool 19 and all were considered as being at serious 
risk of bias overall (Appendix S2).  
   
Outcome data
Indication for referral – Pain
Three studies 15, 20, 30 included women who had been referred for mesh revision surgery because of pain.  
One provided comparative data 15 and found no significant difference in postoperative SUI, pain, or urge 
between complete and partial removal after six weeks.  At 29 weeks follow up, women who had complete 
rather than partial mesh removal were at increased risk of having SUI symptoms (65.4% versus 28.6%, 
respectively, p=0.01) and of having repeat SUI surgery (37.2% versus 14.3%, respectively, p=0.09).15
Overall, mesh removal appears to improve pain outcomes for women following partial or complete 
removal, with resolution of pain reported at 29 weeks by 72% and 76% of women respectively.15 When 
assessed by initial mesh procedure, more women reported being pain-free following sub-urethral 
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Persistent pain following mesh revision was reported by 11.4% of women in this study.  In another study,  
at 12 months follow up 72.5% of women reported some pain improvement following mesh revision 
surgery, 19.3% no change, and 8.2% a worsening of pain.30
Indication for referral – vaginal complications
Two studies 15, 27 included women who had been referred for vaginal complications. One compared 
complete to partial mesh removal in women who had mesh for incontinence.  At 29 weeks follow up, 
more women who had complete mesh removal required SUI reoperation (43.8% versus 8.3%, 
respectively, p=0.02).15  No differences in postoperative SUI, pain, or de novo urgency were reported. The 
second study 27 reported that 16.7% of women had recurrent mesh exposure after mesh revision surgery, 
all requiring a second surgical revision procedure. 
Indication for referral – urinary complications
One study included women who had been referred for urinary complications (voiding symptoms), and had 
initially undergone synthetic midurethral mesh for SUI. 31 Following mesh revision surgery, 23.5% and 
78.9% of women had complete resolution of urge urinary incontinence and of obstructive voiding 
symptoms respectively.  However, de novo urge incontinence and de novo SUI developed in, respectively, 
43.6% and 35.5% of women, with only 22.2% of women reporting that they were satisfied or very satisfied 
with their initial midurethral mesh procedure.31  
Indication for referral – unclear/multiple indicators
Nineteen studies reported outcomes following mesh revision surgery, although they did report them 
according to the specific indication for referral.  Three  compared complete to partial mesh removal,14, 16, 
25 one compared complete removal to segment excision29, and one  compared mesh division to mesh 
excision. 28 
Comparative studies
One study, with a mixed cohort of women (initial mesh surgery for either incontinence or prolapse)25 
found that more women had recurrent SUI and recurrent cystocele following complete mesh removal 
compared to partial removal, but this was not statistically significant.  Another study, including women all 
who had initial mesh surgery for incontinence, did not find a difference in incontinence outcomes 
following complete mesh removal and mesh excision; 36.7% of women in this study required a second 
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that, compared to mesh division, mesh excision resulted in significantly more women experiencing 
recurrent SUI symptoms (56.1% versus 13%, respectively, p =0.02) and having a reoperation for SUI 
(28.1% versus 4.4%, respectively, p=0.002).28
One study reported no significant difference in pain resolution between women who had complete 
compared to partial mesh removal (58.1% versus 70.1%, respectively, p=0.4).14  Overall, complete 
resolution of presenting symptoms was reported in 51.1% of women who had mesh removal surgery. 
However, 30% of women who had dyspareunia before revision surgery reported that it persisted at follow 
up.14
Only one study reported HRQOL,16 with a statistically significant improvement in the SF-12 mental 
composite score reported by women who had complete mesh removal compared to those who had 
partial removal. No other differences were reported in HRQOL as assessed by other scales (SF-12 physical 
composite score, Pelvic Floor Distress Inventory 20 (PFDI-20), Pelvic Organ Prolapse Distress Inventory 6 
(POPDI-6), Colorectal-Anal Distress Inventory 8 (CRADI-8) or Urinary Distress Inventory 6 (UDI-6) 
questionnaires).16
Non-comparative studies 
Improvement in overall symptoms 
Five studies 14, 23, 24, 35, 36 reported an overall change in symptoms following mesh revision surgery, with the 
number of women experiencing symptom resolution varying from 24% 35 to 80% 24.  One reported that 
80% of women who had mesh revision surgery experienced some symptom improvement as measured by 
the Global Sense questionnaire. 36
Pain 
Ten studies reported on pain outcomes following mesh revision surgery.  The number of women reporting 
complete or significant pain resolution ranged from 19%, 35 36.2% 33 to 97.5% 21 and 100% 26; one 
reported that 78% of women experienced some improvements in pain.36  
Residual or persistent pain was reported as 12% in two studies, 24, 37 7.6% in one study (which included 
dyspareunia), 22 and 24.1% in another.23 One study reported that 23% of women reported no change in 
pain after revision surgery, with 51.5% of the total sample reporting pain (abdominal, buttock, leg, pelvic, 
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Dyspareunia
Seven studies reported dyspareunia following mesh revision surgery.   Improvement in dyspareunia was 
reported in 60% and 86% of women in two studies.35, 38  Following mesh revision surgery, one study 
reported a significant improvement in dyspareunia (p=0.034),38 and significantly reduced Pelvic Floor 
Impact Questionnaire (PFIQ) scores following mesh revision (p=0.02); one study reported dyspareunia was 
much or a little better in 44.9% of women33; one study  reported 30% of women had persistent 
dyspareunia following mesh revision; 25 and one study reported 32.2% of women had dyspareunia, but it 
was unclear if this was de novo or persistent.37   Only one study reported on de novo dyspareunia 
following mesh revision, and this was only reported by one woman.21
Satisfaction
Two studies reported on women’s satisfaction of mesh revision surgery:  64% of women were ‘satisfied’ in 
one study,33 while 46% of women were ‘satisfied’, ‘pleased’ or ‘delighted’ in another 36.
Quality of Life
Two studies reported on quality of life: one study found that women who rated their quality of life as 
‘terrible’ reduced from 48% before revision surgery to 20% (p≤0.05) after;35 one study found significant 
improvements six months after revision surgery on PFDI and PFIQ scores (p=0.004 and 0.002, 
respectively).32
Stress urinary incontinence
Rates of de novo SUI ranged from 5% to 26% after mesh revision surgery.21, 34, 35 One study reported  de 
novo SUI as 11%, 18% and 19% respectively, following midurethral mesh removal, transvaginal mesh 
removal, and mesh removal for both procedures respectively;37  One study reported 52% of women had 
recurrent SUI following revision surgery;26 one study reported that SUI increased from 59% prior to mesh 
revision surgery to 83% after mesh revision surgery;21 one study reported 7.1% of women had persistent 
SUI,34 whilst one study reported 58.1% of women experienced SUI resolution35 and one study found no 
change in SUI scores (as measured by the UDI scale). 36
Urge urinary incontinence
Urinary urge incontinence (UUI) was reported in various ways across studies:  One study reported de novo 
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transvaginal mesh removal (15%) and mesh removal for both procedures (25%) of women with de novo 
UUI.37  Another study reported a de novo UUI rate of 63% (although this data was only from women who 
had returned for follow up).  When the UUI rate was calculated from the whole cohort, this was 21.2% 22;  
one study reported 1% of women had de novo UUI,32 whilst 6.1% had persistent UUI.34  Resolution of UUI 
was reported in 36.4% of women in one study. Two studies 33, 36  reported no change in UUI (as measured 
by the MESA score or UDI scores). 
Mesh exposure
Two studies reported on mesh exposure or extrusion following mesh revision surgery:  One reported 9% 
of women had persistent mesh exposure after surgery,23 while the other study  reported only one case of 
mesh exposure.22 
Repeat mesh revision procedures
Studies did not consistently report the number of procedures received by women nor what additional 
mesh revision procedures were performed.  One study reported that 11% of women had repeat revision 
surgery, with 50% of the whole sample needing some additional treatment; 39  one study reported that 
20% of women required more than two repeat interventions for mesh complications.40  A further study, 
reported that 16.6% of women had one or more additional treatments for pain after mesh removal.36  
These studies all included women having revision surgery following incontinence mesh procedures or 
mesh for POP.  
One study reported that 30% of women had already undergone treatment for mesh complications, 
indicating that these women needed at least one or more mesh revisions.23 Another reported that 29.3% 
of women required repeat mesh excision 35. In these two studies women had all had initial mesh surgery 
to treat prolapse.  One study, where all women initially had mesh for incontinence showed 20.5% of 
women had multiple procedures for mesh revision.29 
Recurrent POP
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Studies did not consistently report adverse events due to mesh revision surgery. The available data 
suggests that the injury rate is low, with all studies reporting rates less than 4% for bladder, urethra or 
bowel injury during surgery 16, 21, 24, 25, 32, 35, 37, 39; the injury rate in half of these studies was 1% or less.21, 24, 
31, 32, 35 One study reported that 3% of women required a blood transfusion during surgery.39 
Discussion
Main finding
Overall, this review shows that there is little evidence on the effective management of mesh 
complications.  The majority of studies did not specify the indicator for referral, studies pooled outcomes 
across all revision surgery procedures, and few compared different management strategies.  The very low 
quality of the evidence therefore made it difficult to draw firm conclusions, or to provide strong 
recommendations for how mesh-related complications should be managed.
Strengths and Limitations
This review describes a body of evidence not previously synthesised.  We used robust methodology, 
including an inclusive search strategy encompassing multiple databases; however, as this review was 
conducted as part of the recently published NICE guideline, more research may have since been 
published.
We have fully described the included studies and extracted data on a range of complications.  The main 
limitation is the inclusion of low quality evidence: the majority of studies were not comparative in design, 
did not examine treatments according to complication type, and did not compare outcomes according to 
different management strategies. Interpretation of the evidence is therefore difficult. Also we found no 
studies that included women specifically referred for bowel complications or that provided data on 
conservative treatments. Finally, the majority of studies did not report outcomes according to the 
indication for referral, essential information for determining the effective management of complications. 
Interpretation of results
Due to the paucity of data, reliable estimates of the effect sizes of the different revision procedures are 
not possible and so a narrative synthesis was presented.  Although the included studies provided data on 
women who had received treatment for mesh complications, various mesh products were used in the 










This article is protected by copyright. All rights reserved
Few of the included studies directly compared complete mesh removal with partial removal. However, 
the evidence suggests that complete rather than partial mesh removal results in an increased risk of 
experiencing recurrent urinary complications, and this was shown in studies where women had originally 
had mesh surgery for SUI or POP.15, 25, 31  
This review found that mesh removal surgery can resolve complications associated with mesh surgery for 
SUI and/or POP. However, the reported success rate varies widely; for example mesh removal resulted in 
between 19% and 100% of women experiencing pain resolution across studies.  After removal, some 
women may have persistent problems, develop de novo complications, or need additional surgery for 
complications arising from the revision surgery itself. 
Conclusion
The current evidence is not sufficient to support strong recommendations on how mesh complications 
should be managed in women who have had mesh surgery for SUI, POP or both.
The review shows that women can present with more than one mesh-related complication and may have 
persistent symptoms after mesh removal surgery.  Given the variety of these persisting symptoms, input 
from a range of professionals is likely to be required.   Therefore, as recommended in the updated NICE 
guideline, women who are considering mesh revision surgery should be given the opportunity to discuss 
their case with the relevant specialist multidisciplinary teams.17 
Practical recommendations
Clinicians should discuss the different treatment options with a woman who is experiencing complications 
associated with mesh.  She should be informed that:
 surgery to remove mesh may not relieve symptoms and may lead to further complications 
 urinary incontinence or prolapse can recur  
 removing part of the mesh may be as effective as complete removal.  
Health care professionals should refer to the published NICE guideline for full recommendations on 
management of mesh complications.  Furthermore, because of safety concerns associated with mesh 
products, robust data on the effective management of mesh-related complications is required and a 
national registry to collect data is needed to provide both accurate estimates of complication rates and 
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The review highlights the lack of high quality evidence on the effective management of mesh 
complications following mesh surgery for SUI, POP, or both.  Evidence on how to best manage mesh 
related complications is urgently required; robustly conducted cohort studies, and ethically sound RCTs 
should be developed to determine effective management strategies for the different complications which 
women present with.
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